- Home
- LNZA vs TSHA Comparison
LNZA vs TSHA Comparison
Compare LNZA & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- TSHA
- Stock Information
- Founded
- LNZA 2005
- TSHA 2019
- Country
- LNZA United States
- TSHA United States
- Employees
- LNZA N/A
- TSHA N/A
- Industry
- LNZA Major Chemicals
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- TSHA Health Care
- Exchange
- LNZA Nasdaq
- TSHA Nasdaq
- Market Cap
- LNZA 65.7M
- TSHA 728.4M
- IPO Year
- LNZA N/A
- TSHA 2020
- Fundamental
- Price
- LNZA $0.29
- TSHA $2.56
- Analyst Decision
- LNZA Hold
- TSHA Strong Buy
- Analyst Count
- LNZA 2
- TSHA 6
- Target Price
- LNZA $2.00
- TSHA $8.17
- AVG Volume (30 Days)
- LNZA 1.8M
- TSHA 2.9M
- Earning Date
- LNZA 08-07-2025
- TSHA 08-11-2025
- Dividend Yield
- LNZA N/A
- TSHA N/A
- EPS Growth
- LNZA N/A
- TSHA N/A
- EPS
- LNZA N/A
- TSHA N/A
- Revenue
- LNZA $48,831,000.00
- TSHA $7,224,000.00
- Revenue This Year
- LNZA $58.17
- TSHA N/A
- Revenue Next Year
- LNZA $10.92
- TSHA N/A
- P/E Ratio
- LNZA N/A
- TSHA N/A
- Revenue Growth
- LNZA N/A
- TSHA N/A
- 52 Week Low
- LNZA $0.14
- TSHA $1.05
- 52 Week High
- LNZA $2.74
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- LNZA 51.55
- TSHA 54.79
- Support Level
- LNZA $0.27
- TSHA $2.33
- Resistance Level
- LNZA $0.32
- TSHA $2.73
- Average True Range (ATR)
- LNZA 0.03
- TSHA 0.14
- MACD
- LNZA -0.00
- TSHA 0.02
- Stochastic Oscillator
- LNZA 50.54
- TSHA 70.53
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.